Nurix Therapeutics, Inc. SEC filings NRIX

Nurix Therapeutics, Inc. has 561 filings in SEC EDGAR's recent list, going back to May 15, 2012. Its latest annual report, Form ARS, was filed on Mar 27, 2026 for the period ended Nov 30, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 13, 2026, covering the quarter ended Aug 31, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (other events). The company's fiscal year ends on November 30.

Form Description Filed Period
DEFA14A Additional proxy material Mar 27, 2026 —
DEF 14A Proxy statement Mar 27, 2026 May 15, 2026
DEFA14A Additional proxy material Mar 28, 2025 —
DEF 14A Proxy statement Mar 28, 2025 May 19, 2025
DEFA14A Additional proxy material Mar 27, 2024 —
DEF 14A Proxy statement Mar 27, 2024 May 20, 2024
DEFA14A Additional proxy material Mar 24, 2023 —
DEF 14A Proxy statement Mar 24, 2023 May 4, 2023
DEFA14A Additional proxy material Mar 25, 2022 —
DEF 14A Proxy statement Mar 25, 2022 May 5, 2022
DEFA14A Additional proxy material Mar 25, 2021 —
DEF 14A Proxy statement Mar 25, 2021 May 6, 2021

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NRIX (Nasdaq)
Fiscal year ends
November 30
Incorporated in
DE
Headquarters
Brisbane, CA
SEC filer status
Large accelerated filer
SEC CIK
1549595
Former names
Nurix, Inc. (until Sep 18, 2015)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.